2021
Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis
Mayén-Lobo YG, Martínez-Magaña JJ, Pérez-Aldana BE, Ortega-Vázquez A, Genis-Mendoza AD, de Montellano D, Soto-Reyes E, Nicolini H, López-López M, Monroy-Jaramillo N. Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis. Pharmaceuticals 2021, 14: 118. PMID: 33557049, PMCID: PMC7913835, DOI: 10.3390/ph14020118.Peer-Reviewed Original ResearchRefractory psychosisPolygenic risk scoresMood stabilizersMetabolic ratioOnly antipsychotic drugUse of clozapineEffective mood stabilizerCLZ treatmentAntipsychotic drugsRisk scoreClozapineBipolar disorderLarger sample sizePatientsPsychosisGABAergic synapse pathwayBD-PRSFuture studiesSample sizeHigh-impact variantsAntipsychoticsPathwayFindingsMethylome profilesComplex mechanisms
2019
Differential effects on neurodevelopment of FTO variants in obesity and bipolar disorder suggested by in silico prediction of functional impact: An analysis in Mexican population
Saucedo‐Uribe E, Genis‐Mendoza A, Díaz‐Anzaldúa A, Martínez‐Magaña J, Tovilla‐Zarate C, Juárez‐Rojop I, Lanzagorta N, Escamilla M, González‐Castro T, Narvaez M, Hernández‐Díaz Y, Nicolini H. Differential effects on neurodevelopment of FTO variants in obesity and bipolar disorder suggested by in silico prediction of functional impact: An analysis in Mexican population. Brain And Behavior 2019, 9: e01249. PMID: 31033179, PMCID: PMC6576176, DOI: 10.1002/brb3.1249.Peer-Reviewed Original Research